SCHEMBL10003298

SCHEMBL10003298

CCOC(=O)c1c(OCC(F)(F)F)c2cc(-c3ccc(CC)cc3)c(CC)nc2n1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.37
▸ GAA P10253 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ GRM2 Q14416 1/20 0.35
▸ KDM4E B2RXH2 4/20 0.35
▸ MAPT P10636 3/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ HSP90AA1 P07900 1/20 0.35
▸ CRHBP P24387 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ CRHR2 Q13324 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ MAOB P27338 1/20 0.35
▸ IDO1 P14902 1/20 0.34
▸ ALPI P09923 1/20 0.34
▸ ENPP2 Q13822 1/20 0.34
▸ HDAC4 P56524 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34
▸ GABRA2 P47869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003955 0.94 ALDH1A1 (0.40) ALDH1A1GAAL3MBTL1KDM4EMAPT
SCHEMBL10003637 0.94 MAPT (0.40) ALDH1A1GAAL3MBTL1KDM4EMAPT
SCHEMBL10003348 0.94 ALDH1A1 (0.44) ALDH1A1GAAL3MBTL1GRM2KDM4E
SCHEMBL10004077 0.93 GABRA2 (0.41) ALDH1A1GAAL3MBTL1KDM4EMAPT
SCHEMBL10003156 0.93 KDM4E (0.41) ALDH1A1GAAKDM4EMAPTMEN1
SCHEMBL12003592 0.92 POLB (0.42) ALDH1A1GAAL3MBTL1KDM4EMAPT
SCHEMBL10003679 0.92 MLYCD (0.40) ALDH1A1GAAKDM4EHPGD
SCHEMBL10003383 0.90 ALPI (0.35) L3MBTL1ALPI
SCHEMBL10004644 0.90 ALDH1A1 (0.37) ALDH1A1GAAL3MBTL1KDM4EMAPT
SCHEMBL10003072 0.89 TP53 (0.39) ALDH1A1GAAL3MBTL1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH ALDH1A1 321/4885GAA 3144/4885L3MBTL1 2806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback